GOOD READS

HistoGenetics Selects Illumina’s MiSeq® System as Next-Generation Sequencing Platform of Choice

MiSeq Will Supplement HistoGenetics’ Existing Human Leukocyte Antigen Sequence-Based Typing

RELATED QUOTES

SymbolPriceChange
ILMN135.45-0.77

SAN DIEGO & NEW YORK--(BUSINESS WIRE)--

Illumina, Inc. (ILMN) today announced that HistoGenetics, the leader in high-resolution sequence-based human leukocyte antigen (HLA) testing services, has selected the MiSeq sequencing system for use in its CLIA laboratory. HistoGenetics will deploy multiple MiSeqs to supplement its existing Sanger sequencing workflow to sequence HLA genes with high accuracy and speed. In addition to their utility in tissue matching for transplants, HLA gene variations have known associations with a wide variety of autoimmune diseases, infectious diseases, and some cancers.

Despite their importance, HLA genes have not been routinely typed at higher resolution because of the technical challenges of accurately discriminating between these highly related genes and their many alleles. HistoGenetics, one of the largest HLA typing laboratories in the world, has previously implemented Sanger sequencing as the sole method for higher resolution HLA typing. With its deployment of MiSeqs, HistoGenetics will lead the transition from Sanger sequencing to next-generation sequencing for HLA typing.

“We anticipate building on our leadership position and established success by leveraging the MiSeq platform,” said Dr. Nezih Cereb, Chief Executive Officer and Co-founder of HistoGenetics. “Based on our experience with other technologies, we think the MiSeq’s quality data output and simple workflow, combined with Illumina’s commitment to work collaboratively, is the ideal solution to enable us to provide our customers with the superior results and turnaround time they require.”

HistoGenetics currently provides two levels of resolution with HLA sequencing-based testing, including high-level and registry-level resolution. At high resolution, the most comprehensive level, all ambiguities are resolved in the antigen recognition sites, and new and rare alleles missed by other methods typically can be found. The American Society for Histocompatibility and Immunogenetics and the National Marrow Donor Program require this level of testing for stem cell transplants. At the registry level, which is used for unrelated donor registries (such as the Be The Match RegistryTM) and cord blood banks, a majority of ambiguities are resolved.

“By introducing the MiSeq, we will be able to provide gold-level high resolution typing to pre-transplant work-ups, as well as to registry donors, and improve the turnaround time for sample processing,” added Dr. Cereb.

HistoGenetics’ turnaround time for typing services is currently as short as three days for urgent samples. To date, HistoGenetics has typed more than 3 million samples and performed more than 13 million sequence-based typings that led to the discovery of more than 16,000 samples carrying a new variant of an HLA allele.

“Next-generation sequencing has the potential to transform HLA genotyping, and we believe Illumina’s technology is well-positioned to help drive that change,” said Matt Posard, Senior Vice President and General Manager of Illumina's Translational and Consumer Genomics business. “The MiSeq can make a significant difference in terms of accuracy and speed for production-scale HLA typing. We look forward to a successful relationship with HistoGenetics.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

About HistoGenetics, LLC

HistoGenetics (www.histogenetics.com) is the global leader in HLA sequence-based typing (SBT). As a pioneer the field, the company has provided its services for donor registries, donor centers, cord blood typing, transplant centers, HLA laboratories and pharmacogenomics applications. To date, HistoGenetics has performed more than 13 million SBTs and discovered 16,000 samples carrying new alleles. The company was founded by Dr. Soo Young Yang, who serves as Chairman, and Dr. Nezih Cereb, Chief Executive Officer.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

Contact:
Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com

Quiz: How well do you know India's economy?

Question 1

Which of these products is India the world's largest producer of?

Poll Choice Options
  • Wheat
  • Rice
  • Milk
1
2
3
4
5
6
7
8
9
10

Latest News

  • GM to battle VW in China with $12 bln investment and new plants

    U.S. car giant General Motors Corp (GM) (GM.N) plans to invest $12 billion in China from 2014 to 2017 and build more plants next year as it competes with aggressive rivals in the world's largest auto market. GM expects its China sales to expand 8-10 percent this year, in line with the overall growth of the Chinese market, where foreign firms, such as Volkswagen AG (VOWG_p.DE), and domestic players like SAIC Motor Corp vie for more market share. In total we are investing $12 billion between …

  • Mercedes, BMW chase ultra rich clients with new high end cars

    Premium auto maker BMW (BMWG.DE) unveiled a luxury concept sedan in Beijing on Sunday, to gauge customer appetite for a car that would cost more than German manufacturer's current flagship 7 series limousine. Ian Robertson, BMW Group's board member responsible for sales and marketing said the car is being presented the Auto China show in Beijing as a way to test customer opinion in the world's largest car market. Around half of tall the 7-series flagship models made by BMW end up being sold …

  • Reliance rubber unit sets up customer support in Vadodara

    Mumbai, April 20 (IANS) Relflex Elastomers, the synthetic rubber business unit of Mukesh Ambani-led Reliance Industries Ltd (RIL), Sunday inaugurated a customer support centre at its petrochemicals complex ... …

  • GM to invest $12 bln in China and plans more plants

    U.S. car giant General Motors Corp (GM) (GM.N) plans to invest $12 billion in China from 2014 to 2017 and build more plants next year as it steps up its presence to compete with aggressive rivals in the world's largest auto market. GM expects its China sales to expand 8-10 percent this year, in line with the overall growth of the Chinese market, where foreign firms, such as Volkswagen AG (VOWG_p.DE), and domestic players like SAIC Motor Corp vie for more market share. In total we are …

  • In the driving seat: China's yuppies are new market force for global a …

    SHANGHAI/BEIJING (Reuters) - Global automakers are scrambling to meet the demands of China's young urban professionals, who want a car that makes them stand out, yet don't always have the money to splurge on a top-end model. After nearly two decades of frenzied growth driven mainly by the very wealthy, China's auto market is maturing, yet remains ferociously competitive with manufacturers having to react quickly to shifting consumer trends. People like Zhou Wenxi, a 32-year-old Shanghai …

IN-DEPTH ANALYSIS & INTERVIEWS

  • This might well be India’s biggest Ponzi scam

    It was just too good to be true. Ashok Khital, 45, displays every symptom of a man who knows he's been conned. …

  • India's star studded football league

    High and mighty including Sachin, Salman & Sun Group buy ISL teams …

  • Leaderspeak with Rajesh Janey

    Rajesh Janey, President - India & SAARC, EMC shares many firsts in his life. …

  • Seed of Doubt

    Field trials have been allowed again in India. But two decades after their global launch, genetically modified (GM) crops remain controversial. …

  • Power Hungry

    Gujarat has power round-the-clock. Most other states do not. Why this will matter in the general elections. …

  • Etcetera

    The most keenly watched contest of the current general election will be the one for the Varanasi parliamentary seat, where the Bharatiya Janata Party's prime ministerial hopeful Narendra Modi squares off ... …

  • Economy vs Democracy

    As the country gets election fever, cash comes out of mattresses and turns into liquor, gifts, and food. But it is not bad for the health of the economy, reports Sarika Malhotra from the trenches. …

MARKET MOVERS

  • Most Actives
    Most Actives
    NamePriceChange% Chg
    16.52+0.88+5.63%
    UNITECH.BO
    73.85+3.05+4.31%
    HDIL.BO
    13.36+0.25+1.91%
    SUZLON.BO
    718.55-6.70-0.92%
    HDFCBANKSL.BO
    57.40+2.75+5.03%
    JAIPRA.BO
  • Price % Gainers
    Price % Gainers
    NamePriceChange% Chg
    12.60+2.10+20.00%
    AGRIMONY.BO
    242.50+40.40+19.99%
    ACRYSIL.BO
    83.50+13.90+19.97%
    SICAL.BO
    46.00+7.65+19.95%
    SHRGLTR.BO
    65.25+10.85+19.94%
    AHLUCONT.BO
  • Price % Losers
    Price % Losers
    NamePriceChange% Chg
    11.60-2.70-18.88%
    ANISHAIMPEX.BO
    51.10-8.85-14.76%
    WINSOMTX.BO
    11.70-1.30-10.00%
    BLCISER.BO
    425.00-40.00-8.60%
    GCMSECU.BO
    59.40-5.55-8.55%
    JBML.BO
  •  
    Recent Quotes
    Symbol Price Change % ChgChart 
    Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.
    You need to enable your browser cookies to view your most recent quotes.
  • Recent Quotes News

    •  
      Sign-in to view quotes in your portfolios.